Insulet (PODD) Cash from Financing Activities (2010 - 2026)
Insulet's (PODD) quarterly Cash from Financing Activities came in at -$319.9 million in Q1 2026, down 215.2% YoY from $277.7 million in Q1 2025, and down 341.24% on a QoQ basis from -$72.5 million in Q4 2025.
Insulet (PODD) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Insulet (PODD) has 17 years of Cash from Financing Activities data on file, last reported at -$319.9 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 215.2% year-over-year to -$319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 552.2% YoY) and the FY2025 annual result came in at -$595.3 million, down 2026.07% from the prior year.
- Cash from Financing Activities fell to -$319.9 million in Q1 2026, from -$72.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $277.7 million in Q1 2025 to a low of -$457.0 million in Q3 2025.
- A 5-year average of -$58.7 million and a median of -$12.1 million in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 2069.5% in 2025, down 23952.63% in 2025.
- Tracing PODD's Cash from Financing Activities over 5 years: stood at -$14.5 million in 2022, then surged by 115.17% to $2.2 million in 2023, then tumbled by 1045.45% to -$20.8 million in 2024, then sank by 248.56% to -$72.5 million in 2025, then slumped by 341.24% to -$319.9 million in 2026.
- The last three Cash from Financing Activities figures came in at -$319.9 million (Q1 2026), -$72.5 million (Q4 2025), and -$457.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Insulet | 10.34 Bn | 9.80 Bn | 562.60 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | -319.90 Mn |
| Mar 31, 2026 | -319.90 Mn |
| Dec 31, 2025 | -72.50 Mn |
| Dec 31, 2025 | -72.50 Mn |
| Sep 30, 2025 | -457.00 Mn |
| Sep 30, 2025 | -457.00 Mn |
| Jun 30, 2025 | -343.50 Mn |
| Jun 30, 2025 | -343.50 Mn |
| Mar 31, 2025 | 277.70 Mn |
| Mar 31, 2025 | 277.70 Mn |
| Dec 31, 2024 | -20.80 Mn |
| Dec 31, 2024 | -20.80 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | -14.10 Mn |
| Mar 31, 2024 | -14.10 Mn |